BIOMAT Database Logo BIOMAT Database Logo

Icodextrin-based continuous ambulatory peritoneal dialysis therapy effectively reduces left ventricular mass index and protects cardiac function in patients with end-stage renal disease. 2013

Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Division of Nephrology, Kokura Memorial Hospital, Kitakyushu, Japan. iku-ohba@med.tohoku.ac.jp

Increased left ventricular mass index (LVMI) is commonly observed in patients undergoing peritoneal dialysis (PD). The present study aimed to determine the effect of icodextrin (Ico) on LVMI in PD patients with maintained residual renal function (RRF). This retrospective study included 18 patients (12 men, 6 women; average age: 62 +/- 10 years) diagnosed with indications for PD therapy and divided into two groups: those treated with Ico (Ico group) and without Ico (non-Ico group). Echocardiography was performed at the beginning of continuous ambulatory PD and after 6 and 12 months. A significant reduction in LVMI (p < 0.01) and an increase in ultrafiltration (p < 0.01) were observed after 6 months of lco treatment and were maintained for 12 months. Ejection fraction was significantly lower in the non-Ico group after 12 months (p < 0.01), but was not altered in the Ico group. Blood pressure, cardiothoracic ratio, urine volume, and N-terminal prohormone of brain natriuretic peptide were unaffected by PD treatment up to 12 months. The year-averaged ultrafiltration and the reduction in LVMI were significantly correlated (p < 0.05). Ico effectively improved LVMI and maintained ejection fraction in end-stage renal disease patients within 1 year from PD initiation. Notably, treatment with Ico resulted in a reduction of LVMI (associated with increased ultrafiltration), with no significant reduction in RRF.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D005260 Female Females
D005936 Glucans Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. Glucan,Polyglucose,Polyglucoses,Glucan (BO),Glucose Polymer,Polycose,Polymer, Glucose
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077607 Icodextrin A glucan that is structurally related to maltodextrin, with more than 85% of its molecules having molecular weights between 1640 and 45 000 Daltons (Da), and a weight-average molecular weight of about 20 000 Da; it is used in dialysis fluids as an alternative to glucose-based solutions, and to reduce adhesions after gynecological or abdominal surgery. It has also been used as a vehicle for drugs given via the peritoneal cavity. Extraneal,Icodial

Related Publications

Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Left Ventricular Mass Index in End-Stage Renal Disease Patients during Hemodialysis and Continuous Ambulatory Peritoneal Dialysis.
January 2023, International journal of clinical practice,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Continuous ambulatory peritoneal dialysis therapy for patients with end stage renal disease.
March 1990, Journal of gerontological nursing,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Continuous ambulatory peritoneal dialysis for patients with severe left ventricular systolic dysfunction and end-stage renal disease.
May 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Continuous ambulatory peritoneal dialysis in end-stage renal disease.
June 1983, Israel journal of medical sciences,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Cardiac surgery in patients with end-stage renal disease. Utility of continuous ambulatory peritoneal dialysis.
February 2001, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
September 2000, The Journal of clinical endocrinology and metabolism,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Continuous ambulatory peritoneal dialysis for the end stage renal disease patients.
November 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease.
March 1982, The New England journal of medicine,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease.
October 1982, The New England journal of medicine,
Ikuko Oba, and Michiya Shinozaki, and Kenji Harada, and Takefumi Mori, and Hidetoshi Kanai
Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis.
January 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
Copied contents to your clipboard!